Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: metacrine.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/22/2021 | $2.50 | Outperform → Sector Perform | RBC Capital Mkts |
10/22/2021 | $19.00 → $1.00 | Buy → Hold | Canaccord Genuity |
10/22/2021 | $14.00 → $2.00 | Buy → Hold | Jefferies |
10/22/2021 | Buy → Neutral | HC Wainwright & Co. |
RBC Capital Mkts downgraded Metacrine from Outperform to Sector Perform and set a new price target of $2.50
Canaccord Genuity downgraded Metacrine from Buy to Hold and set a new price target of $1.00 from $19.00 previously
Jefferies downgraded Metacrine from Buy to Hold and set a new price target of $2.00 from $14.00 previously
HC Wainwright & Co. downgraded Metacrine from Buy to Neutral
H.C. Wainwright initiated coverage of Metacrine with a rating of Buy and set a new price target of $15.00
Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.
SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity. Dr. Chen's resignation is effective December 31, 2021. Preston Klassen, M.D., MHS, chief executive officer, is expected to assume responsibility for Metacrine's ongoing clinical trials and future clinical operations. "We appreciate Hubert's significant contributions during the last three years as we moved our pipeline through several important milestones," said Preston Klass
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee. “We’re excited to welcome Julia as a new independent director,” commented Richard Heyman, Ph.D., Metacrine’s chairman. “She is an accomplished biopharmaceutical executive, with an established track record in building companies, business development, capital formation and strategic partnerships. Juli
4 - Metacrine, Inc. (0001634379) (Issuer)
4 - Metacrine, Inc. (0001634379) (Issuer)
4 - Metacrine, Inc. (0001634379) (Issuer)
4 - Metacrine, Inc. (0001634379) (Issuer)
4 - Metacrine, Inc. (0001634379) (Issuer)
4 - Metacrine, Inc. (0001634379) (Issuer)
4 - Metacrine, Inc. (0001634379) (Issuer)
3 - Metacrine, Inc. (0001634379) (Issuer)
4 - Metacrine, Inc. (0001634379) (Issuer)
4 - Metacrine, Inc. (0001634379) (Issuer)
15-12G - Metacrine, Inc. (0001634379) (Filer)
8-K - Metacrine, Inc. (0001634379) (Filer)
S-8 POS - Metacrine, Inc. (0001634379) (Filer)
S-8 POS - Metacrine, Inc. (0001634379) (Filer)
8-K - Metacrine, Inc. (0001634379) (Filer)
8-K - Metacrine, Inc. (0001634379) (Filer)
EFFECT - Metacrine, Inc. (0001634379) (Filer)
25-NSE - Metacrine, Inc. (0001634379) (Subject)
DEF 14A - Metacrine, Inc. (0001634379) (Filer)
8-K - Metacrine, Inc. (0001634379) (Filer)
SC 13G/A - Metacrine, Inc. (0001634379) (Subject)
SC 13G/A - Metacrine, Inc. (0001634379) (Subject)
SC 13G - Metacrine, Inc. (0001634379) (Subject)
SC 13D - Metacrine, Inc. (0001634379) (Subject)
SC 13G/A - Metacrine, Inc. (0001634379) (Subject)
SC 13G/A - Metacrine, Inc. (0001634379) (Subject)
SC 13G/A - Metacrine, Inc. (0001634379) (Subject)
SC 13D/A - Metacrine, Inc. (0001634379) (Subject)
SC 13G - Metacrine, Inc. (0001634379) (Subject)
SC 13G - Metacrine, Inc. (0001634379) (Subject)
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors." About Metacrine Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies t
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. "We made great progress during the quarter in advancing our proposed merger with Equillium," said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. "We believe that Equillium has demonstrated compelling clinical data in Lupus Nephritis and has an exciting pipeline of clinical programs with multiple upcoming data catalysts and potential value inflection events. Equillium is led by an accomplished leadership
Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its second-quarter 2022 financial results. "We have made meaningful progress during the quarter in evaluating strategic alternatives designed to maximize stockholder value," said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. Potential strategic alternatives to be explored and evaluated may include a merger, sale, or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of our progr
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its first-quarter 2022 financial results and provided a business update. Metacrine announced today that it has engaged a strategic financial advisor and initiated a review of strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated may include a merger, sale, or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of its programs. "Our cash p
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its fourth-quarter 2021 financial results. "We continue to devote all of our development effort to bringing expanded therapeutic options to people living with ulcerative colitis (UC)," said Preston Klassen, M.D., MHS, CEO, Metacrine. "We have generated preclinical data that supports moving our MET642 program into clinical testing in UC during the next few months. In addition, by reducing our organizational footprint as part of our recently implemented restructuring plan, we ex
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today announced that Ms. Trisha Millican has resigned her position as chief financial officer. Ms. Millican will remain with the Company until March 31, 2022 to ensure a smooth transition. In addition, Mr. Michael York, currently senior vice president, business development and commercial strategy, has been promoted to chief business officer. Mr. York will oversee all business and corporate development activities for Metacrine including evaluation and execution of licensing, partnering and stra
U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitisSufficient capital to complete Phase 2 IBD trial SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that it remains on track to begin a Phase 2 clinical trial in ulcerative colitis. Metacrine has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with its Phase 2 trial evaluating MET642 in subjects with inflammatory bowel disease (IBD) and expects to begin the study in the first half of 2022. To sup
SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity. Dr. Chen's resignation is effective December 31, 2021. Preston Klassen, M.D., MHS, chief executive officer, is expected to assume responsibility for Metacrine's ongoing clinical trials and future clinical operations. "We appreciate Hubert's significant contributions during the last three years as we moved our pipeline through several important milestones," said Preston Klass
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today reported its third-quarter 2021 financial results. "Our recent monotherapy and combination trial results demonstrate the strong therapeutic profile of our FXR program in non-alcoholic steatohepatitis (NASH), while also highlighting the potential of these agents as an important part of combination therapy," said Preston Klassen, M.D., MHS, CEO, Metacrine. "Primarily because of the significant capital required to continue advancing our product candidates, we've halted future c
Gainers HTG Molecular Diagnostics (NASDAQ:HTGM) shares moved upwards by 33.0% to $6.01 during Wednesday's after-market session. This security traded at a volume of 323.6K shares come close, making up 21.6% of its average volume over the last 100 days. The company's market cap stands at $6.1 million. Lannett (NYSE:LCI) shares rose 15.74% to $0.62. The market value of their outstanding shares is at $26.2 million. As per the press release, Q2 earnings came out today. Align Tech (NASDAQ:ALGN) shares rose 15.03% to $325.0. At the close, Align Tech's trading volume reached 121.5K shares. This is 11.8% of its average volume over the last 100 days. The company's market cap stands at $25.3 billion
-Reuters
With US stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. (NASDAQ:EQ) mutually agreed to terminate definitive merger agreement. Metacrine shares jumped 5.4% to $0.4551 in after-hours trading, while Equillium shares dropped 6.3% to close at $0.89 on Friday. Oragenics, Inc. (NYSE:OGEN) disclosed a 1-for-60 reverse stock split. Oragenics shares dipped 6.7% to close at $0.1450 on Friday. Check out our premarket coverage here Pintec Technology Holdings Limited (NASDAQ:PT) reported that its total revenues dropped by 56.53% year-over-year to RMB39.82 million ($5.93 mi
Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors."
Gainers IceCure Medical Ltd (NASDAQ:ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery. Avaya Holdings Corp. (NYSE:AVYA) gained 57% to $0.2384. Athenex, Inc. (NASDAQ:ATNX) surged 47% to $0.1991 after the company announced Quantum Leap Healthcare Collaborative reported a trial result of I-SPY2 trial for oral paclitaxel in combination with PD-1 and carboplatin in neoadjuvant breast cancer. Verona Pharma plc (NASDAQ:VRNA) shares climbed 40.5% to $18.71 after the company announced ensifentrine met primary and key secondary endpoints in t
Gainers IceCure Medical Ltd (NASDAQ:ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery. Exicure, Inc. (NASDAQ:XCUR) shares rose 46% to $1.08 in pre-market trading. Exicure 10% owner CBI USA, Inc. acquired a total of 3,400,000 shares at an average price of $1.60. Verona Pharma plc (NASDAQ:VRNA) rose 39.3% to $18.80 in pre-market trading after the company reported positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.
Gainers Metacrine (NASDAQ:MTCR) stock increased by 27.0% to $0.45 during Monday's after-market session. Today's trading volume for this security ended up closing at 742.5K shares, which is 251.9 percent of its average volume over the last 100 days. The company's market cap stands at $18.9 million. Vallon Pharmaceuticals (NASDAQ:VLON) stock rose 21.28% to $0.38. Trading volume for this security closed at 1.4 million, accounting for 64.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.8 million. Xenetic Biosciences (NASDAQ:XBIO) stock rose 17.81% to $0.33. The market value of their outstanding shares is at $5.0 million. Precigen
-SEC Filing